Introduction
The dimeric AP-1 transcription factor complexes control cell proliferation and dierentiation by regulating gene expression in response to positive and negative stimuli. Various AP-1 components, including c-Jun, are essential for embryonal development and can induce oncogenic transformation upon chronic activation in avian and mammalian cells. Recent studies suggest that the c-Jun dimer partners and their target gene preferences are important determinants in these processes. Here, we will review the dierences between the Jun : Jun, Jun : Fos and Jun : ATF classes of AP-1 dimers with emphasis on their roles in oncogenic transformation in avian model systems. Previous reviews on AP-1 and cell transformation include references: (Angel and Karin, 1991; Wisdom, 1999; Vogt, 1994; Karin et al., 1997; van Dam and van der Eb, 1994; Hagmeyer et al., 1995) .
Jun : Fos and Jun : ATF transcription factors: dimeric complexes with variable composition and activities
AP-1 sub-units: members of the bZip protein family
The main characteristic of the AP-1 complexes in the cell is their heterogeneity in dimer composition. This heterogeneity is caused by the fact that multiple AP-1 sub-units can be expressed at the same time, including c-Jun, JunB, JunD, c-Fos, FosB, Fra1, Fra2, ATF2, ATFa and ATF3. These sub-units belong to the family of bZip proteins, which share the same structural domains for dimerization and DNA binding: a basic region (b) and a leucine zipper (Zip). The basic region harbors the actual DNA-contact surface, whereas the leucine zipper enables the formation of homo-and heterodimeric complexes with other bZip proteins, which is essential for DNA-binding. The DNA-binding and transcription activation domains of the AP-1 subunits can in principle function as independent protein modules. However, they can in¯uence each other's activity as a result of intra-molecular interactions, for instance in the case of c-Jun and ATF2 (Papavassiliou et al., 1995; Li and Green, 1996) . (Hai et al., 1989) . This element only diers by one nucleotide from the heptameric AP1 binding site.
The original distinction between AP1 and ATF/ CREB is somewhat confusing, as Jun : Jun and Jun : Fos dimers can also bind to ATF/CREB sites, depending on the¯anking sequences. Moreover, the ATF/CREB family members can, in fact, be divided into two distinct sub-classes, based on their partner speci®city. The members of the ®rst sub-class, CREB and ATF1, form homodimers or CREB : ATF1 heterodimers, but do not combine with the other ATF proteins. The members of the second sub-class, ATF2, ATFa, CREBP-2, ATF3, ATF4 and ATF6 combine both with themselves and with speci®c Jun and/or Fos family members. For instance, c-Jun forms stable dimers with ATF2, ATF3 and ATF4, but not with ATF1 and CREB. c-Fos and Fra-1 can heterodimerize with ATF4, but not with ATF2 and ATF3 (Ivashkiv et al., 1990; Benbrook and Jones, 1990; Chatton et al., 1994; Hai and Curran, 1991) . Both ATF2 homodimers McCarthy et al. (1995) and Wisdom (1999) and c-Jun : ATF2 heterodimers bind with high anity to degenerated ATF sites with the consensus motif T G / T A CN TCA (Figure 1 ). However, c-Jun : ATF2 and ATF2 : ATF2 show dierences in their relatively anities for more degenerated 8 bp ATF-like motifs Jones, 1990, 1994) .
Jun, Fos and ATF family members can also bind to DNA upon association with certain Maf (Motohashi et al., 1997; Kerpola and Curran, 1996) , C/EBP (Kageyama et al., 1991) , and non-bZip members factors, like NF-kB (Stein et al., 1993) , NFAT (Jain et al., 1993; Chen et al., 1998) , and Smad (Liberati et al., 1999) . This can direct AP-1 components to promoter sequences that only slightly resemble consensus AP1 and ATF motifs. This variation in dimer partner and DNA binding site speci®city is assumed to provide AP-1 sub-units with a high level of¯exibility in gene regulation potential.
Differential control of Jun : Fos and Jun : ATF activity in the cell
The activity of Jun : Fos and Jun : ATF complexes can be regulated at multiple levels. The abundance of the sub-units can be controlled via: (i) regulation of the synthesis and stability of the respective mRNAs; and (ii) regulation of protein stability, e.g. via stimulusdependent degradation via the ubiquitine pathway (Musti et al., 1997) . In addition, the DNA-binding and transactivating capacities of AP-1 components are controlled through post-translational modi®cation (including phosphorylation) and protein ± protein interaction (reviewed in Angel and Karin, 1991; Karin et al., 1997) .
The actual activities of Jun : Fos and Jun : ATF depend on the cell type, its dierentiation state and the type of stimuli it has received. For instance, the Mitogen-Activated Protein Kinase (MAPK) pathways regulate both the amounts and transactivating capacities of the Jun, Fos and ATF proteins in a stimulus-speci®c manner: treatment of ®broblasts or Hela cells with PDGF, serum or phorbol esters predominantly activates the Extracellular-Regulated Kinase (ERK) members of the MAPK family, which leads to strong stimulation of Jun : Fos activity via de novo synthesis of c-Jun : c-Fos, JunB : c-Fos, JunB : c-Fos and JunB : FosB. Treatment of the same cells with stress-inducing stimuli like ultraviolet light or alkylating agents predominantly activates the Jun N-terminal Kinase (JNK)/Stress Activated Protein Kinase (SAPK) members of the MAPK family which preferentially enhance Jun : ATFactivity via phosphorylation of c-Jun-Ser63/73 and ATF2-Thr69/71 located in the respective transactivation domains (Karin et al., 1997; Davis, 1999) . In contrast, activation of protein kinase A by cAMP only strongly enhances de novo synthesis of JunB and c-Fos (Chiu et al., 1988; Flint and Jones, 1991) . A particular stimulus can thus evoke its speci®c`spectrum' of Jun : Fos, Jun : ATF and ATF : ATF activity and thereby activate and/or repress distinct sub-sets of AP-1 target genes (Figure 1 ).
The expression of more than one AP-1 component is under positive and negative AP-1 (auto-) control. The c-jun and atf3 promoters can be activated by cJun : ATF2 and/or ATF2 : ATF2 via Jun : ATF binding sites, whereas the atf3 promoter is inhibited by ATF3 (Angel et al., 1988; Stein et al., 1992; van Dam et al., , 1995 Liang et al., 1996; Wolfgang et al., 2000) . The c-jun promoter can be inhibited by JunB, c-Jun and c-Fos (Chiu et al., 1988; Park, Ponta and Herrlich, unpublished) and c-Fos is also able to inhibit its own promoter (Sassone-Corsi et al., 1988; Konig et al., 1989) . In contrast, c-Jun : Fos and c-Jun : Fra2 positively regulate the expression of Fra1 and Fra2 (Bergers et al., 1995; Sonobe et al., 1995; Schreiber et al., 1997; Matsuo et al., 2000) . This feed-back control allows ®ne-tuned regulation of Jun : Fos and Jun : ATF activity over longer periods of time (Figure 1 ).
Jun : Fos and Jun : ATF dimers as targets of (activated) oncoproteins A large amount of studies have shown that Jun:Fos dimers play an important role in oncogenesis. The c-jun and c-fos genes were identi®ed as retrovirally activated genes with oncogenic potential in avian and mammalian cells. Wild-type c-Jun and Fos(-related) proteins are required for oncogenic transformation induced by constitutively active Ras and Ras-related factors (Lloyd et al., 1991; Smeal et al., 1991; Binetruy et al., 1991; Johnson et al., 1996; Saez et al., 1995; Suzuki et al., 1994) . The levels and/or activity states of c-Jun and c-Fos are elevated by Ras via the JNK/SAPK and ERK pathways (Davis, 1999; Karin et al., 1997; see above) . The levels of Jun : Fra1, rather than of Jun : Fos, are upregulated in Ras-transformed mouse 3T3 cells, in Ras-and Mos-transformed rat thyroid cell lines, and in spontaneous rat and human thyroid tumors (Mechta et al., 1997; Vallone et al., 1997; Battista et al., 1998) . Experimental overexpression of cJun and/or Fra1 in immortalized rodent ®broblasts is sucient to induce oncogenic transformation in the absence of Ras (Mechta et al., 1997; Bergers et al., 1995) . In chicken embryo ®broblasts transformation by v-Src and active versions of Ras and Raf is accompanied by enhanced levels of c-Jun and Fra2, and, in addition, Fra2 hyperphosphorylation (Muramaki et al., 1997; Suzuki et al., 1994) .
Oncogenic Ras can also activate c-Jun : ATF2 via JNK/SAPK(-related) factors. The G-protein coupled receptor encoded by the Mas oncogene product can enhance c-Jun : ATF2 activity via the Ras-related GTPbinding protein Rac (Zohn et al., 1998) . Other cellular oncoproteins that activate c-jun expression and/or the JNK/SAPK and p38 pathways include Db1 (Bar-Sagi and Hall, 2000) and Cot (Chiariello et al., 2000) .
The adenovirus E1A oncoproteins stimulate Jun : ATF2 activity rather than Jun : Fos activity, resulting in enhanced levels of c-Jun : ATF2 and cJun : ATF3 dimers in adenovirus-transformed cells (Hagmeyer et al., 1995 (Hagmeyer et al., , 1996 Liang et al., 1996; van Dam and van der Eb, 1994) . E1A activates Jun : ATF2 dimers by increasing the transactivating capacity of ATF2 via an as yet unknown mechanism (Liu and Green, 1990; Duyndam et al., 1996 Duyndam et al., , 1999 . Whether ATF2 or other ATF family members are essential for transformation by E1A, Ras or other oncogenes remains to be established.
Analysis of the roles of Jun : Jun, Jun : Fos, and Jun : ATF dimers in oncogenic transformation
The studies described above suggest that Jun : Fos and Jun : ATF dimers exhibit distinct functions in cell proliferation, dierentiation, apoptosis and oncogenesis. In addition, Jun homodimers might be involved in oncogenesis, for instance in transformation induced by v-Jun, the activated homolog of c-Jun initially isolated from avian sarcoma virus (ASV) 17 (Maki et al., 1987) . To be able to distinguish between the functions of Jun : Jun, Jun : Fos and Jun : ATF, so-called dimerspeci®c mutants have been developed. These mutants have predominantly been tested in transformation studies with primary chicken embryo ®broblasts (CEFs). Primary CEFs oer the advantage that retroviral overexpression of Jun can induce a transformed phenotype in the absence of an additional cooperating oncogene (Bos et al., 1990; Castellazzi et al., 1990) . Moreover, injection of Jun-transformed CEFs can induce primary ®brosarcomas in the chicken wing (Morgan et al., 1994) .
Oncogenic transformation by artificially stabilized Jun homodimers
To selectively analyse the functions of Jun homodimers, the leucine zipper domain of Jun was replaced by either the corresponding domain of the yeast bZip protein GCN4 or the non-related dimerization domain of the Epstein ± Bar Virus transcription factor EB1 (Hughes et al., 1992; Hartl and Vogt, 1992a; Oliviero et al., 1992; Castellazzi et al., 1993) . These Jun/eb1 and Jun/gcn4 hybrid proteins form very stable homodimers and are unable to dimerize and bind to DNA with wild-type Jun, Fos, or ATF2. In gel shift assays in vitro, the stability of the Jun/eb1-and Jun/gcn4 homodimer-DNA complexes is equivalent to that of the Jun : Fos heterodimer (Jurdic et al., 1995) . Both types of chimeric Jun homodimers were found to eciently activate transcription and to eciently induce oncogenic transformation in chicken and rat embryo ®broblasts (Castellazzi et al., 1993; Jurdic et al., 1995; Vandel et al., 1995 Vandel et al., , 1996 Oliviero et al., 1992) . This suggests either that homodimer-formation of Jun is sucient for transformation, or that Jun homodimers can compensate for Jun : Fos, Jun : ATF and/or other types of Jun dimers.
Arti®cial stabilization of Jun homodimers in fact signi®cantly enhances the oncogenic activity of Jun in CEFs. v-Jun/eb1-transformed CEFs were found to be much more tumorigenic in chickens in vivo than CEFs transformed by`wild-type' v-Jun. When inoculated intravenously into 10-day old chick embryos, recombinant Avian Sarcoma-derived Virus particles harboring v-Jun/eb1 and v-Jun/gcn4 (but not wild-type v-Jun) lead to the development of numerous ®brosarcomas disseminated in the liver, heart, and along the digestive tract (Jurdic et al., 1995) . However, it should be noted that wild-type c/v-Jun is unlikely to form high levels of stable homodimers (Smeal et al., 1989) . In fact, the ability of Jun to bind to consensus Jun : Fos motifs as a homodimer does not seem to be required for transformation of CEFs. V261, a DNA binding domain mutant of Jun that can only bind to 7 bp AP-1 sites after heterodimerization with c-Fos (Ransone et al., 1990), eciently transforms CEFs as measured by induction of anchorage-independent proliferation . It was not examined whether this Jun mutant can still bind to ATF/CREB sites as a homodimer or Jun : ATF heterodimer.
The chimeric homodimers JunB/eb1 and JunD/eb1 can also transform CEFs very eciently, although wild-type JunB transforms only poorly, and wild-type JunD not at all (Castellazzi et al., 1991; Hartl and Vogt, 1992b) . Importantly, the acquired oncogenicity of all of these chimeric Jun proteins is dependent on the N-terminal c-Jun, JunB or JunD transactivation domains. Overexpression of wild-type GCN4 or EB1 does not transform CEFs (Oliviero et al., 1992; Vandel et al., 1995) . An explanation for the enhanced oncogenicity of stabilized Jun homodimers could be that the monomers no longer form non-transforming heterodimers by combining with bZip partners that counteract the transforming activity. However, it cannot be excluded that replacement of the Jun leucine zipper with the EB1 or GCN4 dimerization domains potentiates Jun-induced transformation via other mechanisms. For instance, the introduced dimerization domains might enable the Jun chimeras to interact with proteins with which wild-type Jun does not interact. Or, alternatively, to bind to promoter elements to which the wild-type Jun-containing dimers cannot bind. Anyhow, wild-type Jun : Jun complexes are potentially highly transforming dimers and might for example contribute to oncogenesis as a result of homodimer stabilization in speci®c promoter contexts (Claret et al., 1996) .
Leucine zipper mutants as tools for the analysis of dimer-specific Jun functions
The stabilized Jun homodimers described above can bind both to Jun : Fos and Jun : ATF recognition sites and thus do not reveal clues on the nature of the Juntarget genes involved in transformation. Therefore, attempts were made to construct c-Jun and v-Jun proteins that speci®cally bind to DNA as Jun : Fos and Jun : ATF2. For this purpose, the amino acids were mutated that determine the dimerization speci®city of bZip proteins Schuermann et al., 1991 ; O'Shea et al., 1992; Baxevanis and Vinson, 1993).
Most of these residues are located adjacent to the hydrophobic interphase of the leucine zipper alpha helix ± at the so-called`e' and`g' positions ± and are positively or negatively charged (Figure 2 ). In Fos family members the`e' and`g' positions are strongly negatively charged, whereas in the Jun proteins positively charged amino acids predominate. Electrostatic interactions cause strong stabilization of Jun : Fos heterodimers but destabilize Fos homodimers (Glover and Harrison, 1995; O'Shea et al., 1992) . ATF2 contains equal amounts of positive and negative`e' and`g' residues, which stabilize both ATF2 homodimers and Jun : ATF2 heterodimers. Mammalian twohybrid assays measuring Jun-Fos association in the non-DNA bound state showed that the interaction between c-Jun and c-Fos can be eciently blocked when at least four`e' and/or`g' residues of c-Jun are replaced by negatively charged amino acids. In contrast, the interaction between c-Jun and ATF2 was not inhibited by these mutations van Dam, unpublished) , indicating that dimerization of c-Jun with c-Fos can be selectively aected in the cell. The introduction of`e' and`g' glutamates in the Jun leucine zipper mutant c-Jun-m1 inhibited its ability to bind as a Jun : Fos heterodimer to 7 bp AP-1 sites. In contrast, this mutant showed increased anity for ATF2 upon binding to an 8 bp Jun : ATF site . As this increased anity for ATF2 was not observed in the absence of DNA, the mutations appear to enhance the dimer-stability of Jun : ATF predominantly in the DNA-bound state. The more positively charged c-Jun mutant c-Jun-m0 ± in which the glutamate at position e1 is replaced by a lysine ± shows Fos-over-ATF2 preference in the DNA-bound state as well . The additional eect of DNA-binding on preferential dimerization might be due to the fact that the Nterminal part of the leucine zipper only forms an alpha helix and a coiled-coiled structure in the DNAbound state, in contrast to the C-terminal part of the zipper (Talanian et al., 1990; O'Neil et al., 1990) .
Fos-and ATF-preference of the leucine zipper mutants Jun-m0 and Jun-m1 was con®rmed by transient transactivation studies using Jun : Fos-and Jun : ATF-dependent model promoters. In multiple cell lines (Hela, F9, NIH3T3 and CEF), Jun-m1 only eciently transactivates promoters via Jun : ATF(-like) sites, which can be enhanced by co-addition of ATF2, but not of c-Fos. In contrast, Jun-m0 only can activate transcription via Jun : Fos(-like) sites, which is further enhanced by co-transfection of c-Fos, but not of ATF2 Huguier et al., 1998) . These mutants are, therefore, powerful tools for the analysis of Jun : Fos-and Jun : ATF2-speci®c functions.
The Fos-and ATF-prefering mutants Jun-m0 and Jun-m1 induce distinct transformation programs in CEFs
To examine the roles of Jun : Fos(-like) and Jun : ATF(-like) dimers in oncogenic transformation, the Fos-and ATF-preferring mutants Jun-m0 and Jun-m1 have been retrovirally introduced in CEFs as (human) c-Jun or (avian) v-Jun. Overexpression of exogenous mutant Jun resulted in down-regulation of endogenous avian c-Jun which ensured that the mutant Jun proteins were the predominant Jun proteins present (Castellazzi et al., 1990; Gao et al., 1996; Kilbey et al., 1996; Hartl and Bister, 1998; van Dam et al., 1998) . (The levels of JunD are low in CEFs and appear also to be down-regulated upon transformation by v-Jun; M Hartl, personal communication) Co-immunoprecipitation assays con®rmed that the endogenous avian Fra2 and ATF2 proteins indeed speci®cally interact with the exogenous wild-type or mutant Jun molecules. Fra2 and ATF2 are the only Fos and ATF family members known so far to be constitutively present in the Jun-transformed CEFs (Nishina et al., 1990; Huguier et al., 1998) .
Overexpression of c-Jun-m0 and c-Jun-m1 had similar eects on CEF proliferation as wild-type (human) c-Jun in medium containing high concentrations of serum growth factors, which is a slight increase in doubling time. However, a dierent picture arose when the proliferation of these CEF cultures was analysed under more restricted conditions, i.e. in semi-solid medium (soft agar) and medium containing low concentrations of serum. Only the Jun-m0 expressing cells were able to eciently form colonies in soft agar, whereas only the Jun-m1 transformed cells were able to proliferate in low amounts of serum. Co-expression of the two mutants in the same cells restored the fully transformed phenotype induced by wild-type Jun . This indicates that the Jun-induced transformation program in CEFs can be molecularly separated into two distinct and complementary pathways: uncontrolled Jun : Fos(-like) activity causing anchorage-independence via genes regulated through 7 bp Jun : Fos binding sites; uncontrolled Jun : ATF2(-like) activity triggering growth factor-independence via genes regulated by 8 bp Jun : ATF sites (Figure 1 ).
Differential effects of Jun+ATF2 and Jun+Fra2 on CEFs
The experiments described in the previous section did not reveal conclusive evidence on the exact nature of the Fos-and ATF(-like) partners of Jun involved in transformation. Therefore, CEFs infected with retroviruses expressing only v-Jun, ATF2 or Fra2 were compared with CEFs co-infected with v-Jun-+Fra2-, or v-Jun-+ATF2-expressing retroviruses. Although overexpression of ATF2 by itself does not induce transformation, ATF2 was found to potentiate the ability of v-Jun-and v-Jun-m1 to induce proliferation in low serum medium. In contrast, overexpression of ATF2 slightly, but signi®cantly, inhibited the ability of v-Jun to induce colony formation in agar . This shows that ATF2 is actively involved in the Jun-induced transformation pathway that triggers growth factor-independence. In the case of Fra2, its overexpression did not in¯uence v-Jun-induced CEF colony formation in agar, but almost totally inhibited v-Jun-induced proliferation in low serum (Huguier and Castellazzi; unpublished) . The most likely explanation for these results is that: (1) there is balance between the v-Jun : ATF2 and v-Jun : Fra2 dimers in transformed CEFs and that (2) v-Jun becomes limiting when over-expressed together with ATF2 or Fra2 (Figure 1) .
To con®rm that the enhancement by ATF2 of v-Juninduced autocrine proliferation was due to the enhanced levels of Jun : ATF2 heterodimers, an ATF2 mutant was made in which the ATF2 leucine zipper was replaced by that of c-Fos. This molecule, designated ATF2/fos, cannot form homodimers, but forms Jun:ATF2 heterodimers very eciently. Like wild-type ATF2, ATF2/fos could not induce transformation by itself, but was found to eciently cooperate with v-Jun to allow CEFs to proliferate in low serum medium . These results thus provide strong evidence for a role of Jun : ATF2 heterodimers in CEF transformation.
ATF2 enhances v-Jun-m1 induced primary tumor formation in chickens
Autocrine CEFs transformed by the ATF2-preferring mutant v-Jun-m1 were found to very eciently form primary ®brosarcomas in the chicken wing web. Coinfection with an ATF2-encoding retrovirus further enhanced the already exacerbated tumorigenesis induced by v-Jun-m1 . In contrast, anchorage-independent CEFs expressing the Fos-preferring mutant v-Jun-m0 do not develop ®brosarcomas in vivo. This indicates that primary tumor formation of CEFs is associated with the ability to proliferate in an autocrine fashion rather than in an anchorageindependent manner, which could be related to the low concentrations of growth factors in the chicken wing web.
The contribution of Jun : Fra2-induced anchorageindependent proliferation to avian in vivo oncogenesis is as yet unclear. One could speculate that enhanced levels of Jun : Fra2 dimers will aect cell motility and invasiveness , in line with the role of Jun : Fos in remodeling of the extra-cellular matrix and the presumed role of Jun : Fos during the later stages of oncogenesis (including metastasis) in rodents (Angel and Karin, 1991; Hofmann et al., 1993; Saez et al., 1995; Hennigan et al., 1994; Lamb et al., 1997; Spence et al., 2000) .
Differences in CEF transformation by c-Fos and Fra2
Overexpression of c-Fos or v-Fos induces complete transformation of CEFs, in contrast to the partial transformation induced by v-Jun+Fra2 or the Fosprefering mutant Jun-m0 (Iba et al., 1988; Huguier and Castellazzi, unpublished) . The dimer partner(s) of overexpressed c-Fos in CEFs remain to be determined. The fact that the transactivating capacity of c-Fos is much higher than that of Fra2 suggests that (some of) the target genes of c-Fos involved in transformation might be dierent from the target genes of Jun : Fra2.
Partial transformation of CEFs by ATF3
The ATF3 (LRF-1) protein is like c-Jun and the Fos family members induced by growth factors and stresses in mammalian cells (Hsu et al., 1991; Hai et al., 1999 ). An avian mitogen-and stress-inducible ATF3-like factor has recently been identi®ed in CEF extracts (Perez, van Dam and Castellazzi, unpublished data) . To examine whether ATF3 has transforming properties by itself, the rat ATF3 gene was retrovirally overexpressed in CEFs. The resulting cells display a typical, fusiform morphology and show enhanced proliferation in medium with reduced amounts of serum. However, rat ATF3-overexpressing CEFs do not eciently grow in soft agar, thereby resembling CEFs transformed by the ATF2-preferring mutant Jun-m1 (Perez et al., 2001) . This indicates that ATF3, a potential target gene of Jun : ATF2 in mammalian cells (Figure 1) , has similar eects as Jun : ATF2 on CEFs. However, it remains to be established whether activation of Jun : ATF2 in CEFs leads to an enhanced level or activity of the endogenous avian ATF3. Rat ATF3-expressing CEFs do not form tumors in vivo. Irrespective of this, the ability of ATF3 to speci®cally activate proliferation in low serum, and not in agar might be related to its ability to dierentially regulate Jun : Fos-and Jun : ATF2-dependent genes.
Putative roles of Maf family members interacting with Jun in CEFs
The Maf family of bZip transcription factors was originally identi®ed in avian cells. The members identi®ed so far can be divided into two groups based on their size. The`large' Maf proteins include c-Maf, MafA and MafB; the`small' Maf family members which lack the N terminal activation domain include MafF, MafK and MafG (Motohashi et al., 1997) . cMaf (identical to retroviral v-Maf; Nishizawa et al., 1989) and MafA (Benkhelifa et al., 1998) can form stable heterodimers with Jun and can bind as Jun : Maf heterodimers to the composite DNA motif TGC TGA C TCA GCA, which also contains an internal Jun : Fos site (Kerpola and Curran, 1996) . Upon retroviral overexpression, c-Maf and MafA can induce an oncogenically transformed phenotype in CEF cells (Kataoka et al., 1993; Benkhelifa et al., 1998) . Interestingly, like transformation of CEF by v-Junm1 and ATF3, Maf-induced transformation is incomplete, and restricted to morphological alterations and the ability to proliferate in low serum medium (K Perrigo and M Castellazzi; unpublished) . Whether the endogenous c-Maf and MafA proteins contribute to CEF transformation by Jun, Jun : ATF2 and/or ATF3 or vice versa remains to be established.
Target genes involved in Jun : Fos-and Jun : ATF2-dependent transformation
Transformation and Jun-dependent transcriptional control
It has been well established that Jun-dependent transformation requires the Jun domains that are essential for its ability to function as a transcription factor (leucine zipper, basic DNA contact region and transactivation domain). However, studies in CEFs from P Vogt's laboratory showed no obvious, direct correlation between the transforming potential of Jun (as measured by colony formation in agar) and the transactivating capacity of Jun on the Jun : Fosdependent collagenase promoter (Hartl and Vogt, 1992b; Schuur et al., 1993) . For various Jun mutants and chimera even a reverse correlation was reported (Havarstein et al., 1992) . Other studies from this group indicated that the transforming ability of Jun correlates with its ability to transactivate promoters containing multimerized CREB/ATF sites rather than multimerized Jun : Fos sites (Schuur et al., 1993; Gao et al., 1996) . These results might re¯ect the fact that both positive and negative transcriptional control by Jun contributes to transformation of CEFs (see next paragraph). Obviously, the actual response of a promoter to changes in Jun activity will depend on multiple parameters, including the activity of the Jun dimer partner, other transcription factors and coactivators acting on the promoter, and the promoter architecture (Falvo et al., 2000; Wathelet et al., 1998) . In this respect it should be noted that the Jun, Fos and ATF family members dier in their ability to directly or indirectly interact with the CBP/p300 family of transcriptional co-activators, the Jab1 co-activator, and Swi/Snf chromatin remodeling factors (Lee et al., 1996; Duyndam et al., 1999; Claret et al., 1996; Kawasaki, 1998; Kawasaki et al., 2000; Ito et al., 2001) .
In the case of the Fos-and ATF2-prefering mutants Jun-m0 and Jun-m1, anchorage-independent proliferation was accompanied by enhanced transcriptional activity of a 56collTRE (Jun : Fos)-dependent minimal TK promoter, whereas growth factor-independence was accompanied by enhanced activity of the equivalent 56jun2 (Jun : ATF)-dependent minimal TK promoter. In the latter situation, a direct correlation between Jun : ATF-dependent activation of transcription and v-Jun(-m1)-mediated transformation was found . However, as these transactivation studies have been performed by transient transfection analysis of promoters present on reporter plasmids, it remains to be established whether endogenous Jun : Fos and Jun : ATF-dependent CEF genes behave in a similar manner.
Endogenous genes affected in Jun-transformed cells
Several groups have searched for endogenous genes whose expression is altered upon transformation by Jun. The methods include dierential screening of cDNA libraries and PCR-directed substraction, using cultures of rat (REF), chicken (CEF), or quail (QEF) embryo ®broblasts (Mettouchi et al., 1994; Hartl and Bister, 1995; Hadman et al., 1996; Fu et al., 1999; Perez et al., to be published) . In addition, it was examined whether v-Jun aects genes that are activated or repressed by v-Src . An overview of the results obtained so far is given in Table 1: 14 genes or gene products have been found to be up-regulated by v-Jun, 13 genes have been found to be down-regulated. Strikingly, more than half (15) of the identi®ed genes encode proteins that are located in the extracellular matrix. Nearly all the structural or regulatory extracellular matrix components are down-regulated by v-Jun, with the exception of tenascin C, lysyl oxidase and a1 (I) collagen, whereas three of the four proteases are up-regulated. These changes are in line with the well documented reduction and reorganization of the extracellular matrix in cancer cells, which is thought to facilitate both proliferation and invasive behavior (Benjamin and Vogt, 1990; Hanahan and Weinberg, 2000; Jove and Hanafusa, 1987) .
The activities of urokinase-dependent plasminogen activator (uPA) and 72 kDa gelatinase were found to be enhanced only in (anchorage-independent) CEFs transformed by the Fos-prefering mutant v-Jun-m0, whereas 72 kD gelatinase is repressed in (autocrine) CEFs transformed by the ATF-prefering mutant v-Junm1 . As v-Jun-m1 can repress Jun : Fos and Jun : Fra2 activity in the cell , these results are in agreement with the concept that Jun : Fos-rather than Jun : ATF-dependent genes control cell motility and invasiveness. However, it remains to be established whether the altered expression of urokinase and 72 kDa gelatinase is a direct eect of Jun : Fos(-like) or Jun:ATF(-like) factors on their promoters or whether this is established in a more indirect fashion.
The extracellular matrix components SPARC, ®bro-nectin, decorin, thrombospondin-2, and clusterin are also repressed in CEFs transformed by the ATFpreferring mutant v-Jun-m1 . Down-regulation of the SPARC gene has been found to be important for v-Jun-dependent oncogenesis, as its ectopic re-expression in v-Jun-transformed CEFs strongly reduces the development of tumors in the animal. Represssion of SPARC does not seem to be important for cell transformation in vitro . v-Jun-m1 can inhibit the SPARC promoter , and this seems to be a (relatively) direct eect as it could be observed in transient transfection experiments within 48 h. Although the SPARC promoter does not contain AP-1-or ATF-like binding sites, SPARC expression in CEFs is regulated by various avian AP1 components. Overexpression of c-Jun, JunD, Fra2 and c-Fos inhibits the levels of SPARC, whereas overexpression of ATF2 causes activation. In line with this, Jundependent repression of SPARC is enhanced by Fra2, but counteracted by ATF2 . The latter is somewhat contradictory to the fact that the ATF2-prefering mutant v-Jun-m1 is a much stronger repressor of SPARC than v-Jun(-m0). This and the fact that the SPARC promoter does not contain AP-1-or ATF-like binding sites, still leaves open the possibility that SPARC transcription is indirectly regulated by AP-1 complexes through intermediate transcription factor(s).
Repression of cellular genes by ATF3 in CEFs
As the partial transformed phenotype induced by ATF3 (serum-independent but no anchorage-independent proliferation) is strikingly similar to the (partial) transformed phenotype induced by v-Jun-m1 (Perez et al., 2001) , it was examined whether ATF3 and v-Jun(-m1) have similar eects on CEF gene expression. These studies showed that v-Jun target genes can be divided in three dierent groups. The ®rst group contains ®bronectin, decorin, thrombospondin-2 and par-4, which are down-regulated by both v-Jun-m1 and ATF3. The second group contains collagen XII, clusterin, SPARC, and a2 (I) collagen, which are repressed by v-Jun-m1 but not by ATF3. The third group contains lysyl oxidase and HB-EGF, which are activated by v-Jun but not by ATF3. The absence of a strict coincidence of genes aected by ATF3 and genes aected by v-Jun-m1, including SPARC, is in line with the distinct transformed phenotypes induced by ATF3 and v-Jun-m1 (see above). However, ATF3 and v-Jun(-m1) may induce autocrine growth by repressing similar sub-sets of v-Jun-target genes.
Do Jun : ATF-like dimers play a role in mammalian oncogenesis?
One of the questions raised by the Jun-transformation studies in CEFs is whether c-Jun : Fos(-like) and cJun : ATF2(-like) dimers might play similar roles in oncogenesis of mammalian cells. Interesting clues in this respect are provided by studies on Ras signaling and transformation by human adenoviruses. As described above, c-Jun is essential for transformation of mouse ®broblasts by active Ras. Like v-Juntransformed CEFs, Ras-transformed rodent ®broblasts show an altered morphology including a reduced extracellular matrix, can proliferate in soft agar and low serum media and develop into tumors in nude mice. Three dierent Ras eector pathways need to be activated to establish this complete oncogenic phenotype: the Raf, RalGEF and PI-3 kinase pathways (reviewed in Wolthuis and . Constitutive activation of the Raf eector pathway is predominantly linked to morphological transformation and anchorage-independent proliferation, whereas constitutive activation of the RalGEF eector pathway induces growth factor-independence, but no morphological transformation or colony formation in agar. These partially transformed phenotypes induced by distinct Ras eectors in rodent cells are strikingly similar to the partially transformed phenotypes induced by Jun : Fra2 and Jun : ATF2 in avian ®broblasts. Interestingly, activation of the Raf-MEK-ERK pathway strongly induces c-Jun : Fra1 and c-Jun : Fra2 activity in rodent ®broblasts (Cook et al., 1999;  Figure 1 ), while Rasdependent phosphorylation of c-Jun-Ser63/73 is established via the RalGEF eector pathway (de Ruiter et al., 2000; Hernandez-Munoz et al., 2000) . Moreover, Rlf-caax, an active, membrane targeted, version of the Ral exchange factor Rlf induces c-Jun : ATF2 rather than c-Jun : Fos activity in these ®broblasts (van Dam et al., unpublished) .
A recent study with c-Jun-Ala63/73`knock-in' mice indicates that development of v-Ras-induced skintumors requires phosphorylation of c-Jun-Ser63/73 (Behrens et al., 2000) . Moreover, both c-Jun and ATF2 are transcriptionally activated and N-terminally phosphorylated in cell lines derived from aggressive late stage mouse skin tumors. Enhanced phosphorylation of ATF2 was not observed in cell lines derived from more benign skin tumors (Zoumpourlis et al., 2000) . This could mean that c-Jun : ATF2 contributes to late stages of oncogenesis in the mouse skin. The availability of ATF2 knock-out mice allows this hypothesis to be examined directly.
As mentioned before, rodent and human cells transformed by the adenovirus E1A and E1B proteins contain elevated levels of c-Jun : ATF2 and c-Jun : ATF3. These adenovirus-transformed cells resemble CEFs transformed by ATF3 or the ATF2-prefering mutant v-Jun-m1, as they eciently proliferate in low serum medium, but only ineciently in soft agar (van der Eb, personal communication). At least one mammalian c-Jun : ATF2-dependent gene that is induced by E1A, cyclin A, has also been found to be induced by v-Jun and v-Jun-m1 in CEFs (Buchou et al., 1993; Zerfass et al., 1996; Clark et al., 2000; Vial, Perez, Herrlich and Castellazzi, unpublished;  Figure 1 ). Like v-Jun-m1, E1A can suppress the levels and/or activities of (Jun : Fos-dependent) secreted proteases (van Dam and van der Eb, 1994; see above) . In vivo, adenovirus-transformed BRK cells also resemble CEFs transformed by v-Jun-m1. Both cell types can eciently form primary tumors in immuno-competent animals, but have very low metastatic potential. This suggests that Jun : ATF heterodimers are functionally involved in transformation of mammalian cells by E1A.
Conclusions and future perspectives
Understanding control of gene expression and cell proliferation by the AP-1 family of transcription factors is a complex task as this control is regulated at many dierent levels. In the case of c-Jun, the relative levels of at least three classes of dimers are important: c-Jun : c-Jun, c-Jun : Fos, and c-Jun : ATF. These dimers exhibit speci®c functions during Juninduced transformation of chicken embryo ®broblasts. Enhanced levels of Jun : Fra2 speci®cally trigger the gene program leading to anchorage-independent growth, whereas enhanced levels of Jun : ATF2 induce autocrine growth and primary tumor formation in vivo. Changes in the levels of Fra2 and ATF2 can modulate the eects of Jun : Fra2 and/or Jun : ATF2 dimers on these cells, indicating that the levels of Jun are limiting. It can be anticipated that also other Jun family members can in¯uence cell proliferation by changing the relative levels of c-Jun : c-Jun, c-Jun : Fos, cJun : ATF and ATF : ATF.
Important remaining issues for future research will include the investigation of the roles of ATF3, c-Fos, and Maf proteins in Jun-dependent CEF transformation, as well as further isolation and characterization of Jun : Fos and Jun : ATF target genes relevant to avian oncogenesis. In addition, it will be important to elucidate the speci®c roles of Jun : Jun, Jun : Fos, Jun : ATF and ATF : ATF dimers in mammalian oncogenesis.
